`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`TEVA PHARMACEUTICALS USA, INC. and AKORN INC.,1
`Petitioners,
`v.
`ALLERGAN, INC.
`Patent Owner.
`
`_____________________________
`
`Case IPR2016-01127 (8,685,930 B2)
`Case IPR2016-01128 (8,629,111 B2)
`Case IPR2016-01129 (8,642,556 B2)
`Case IPR2016-01130 (8,633,162 B2)
`Case IPR2016-01131 (8,648,048 B2)
`Case IPR2016-01132 (9,248,191 B2)
`_____________________________
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S
`MANDATORY CHANGE-OF-INFORMATION NOTICES
`
`
`1 Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-
`00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599,
`IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601,
`have respectively been joined with the captioned proceedings. The word-for-word
`identical paper is filed in each proceeding identified in the caption pursuant to the
`Board’s Scheduling Order (Paper 10).
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting
`
`in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”),
`
`hereby submits the following mandatory change-of-information notices in
`
`connection with the inter partes reviews identified in the caption.
`
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised
`
`Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2018-1130 (Fed. Cir.)
`
`(invalidity affirmed November 13, 2018) (EX1163-65; EX1172);
`
`Allergan, Inc. v. Deva Holding A.S., No. 2:16-cv-1447 (E.D. Tex.) (filed
`
`December 22, 2016);
`
`Allergan, Inc. v. Saptalis Pharmaceuticals, LLC, No. 1:18-cv-01231 (D.
`
`Del.) (suit asserting ’162 and ’556 patents voluntarily dismissed January 3, 2019)
`
`(updated);
`
`Allergan, Inc. v. Amneal Pharmaceuticals LLC, No. 1:18-cv-01457 (D. Del.)
`
`(suit asserting ’162 and ’556 patents voluntarily dismissed January 3, 2019)
`
`(updated);
`
`St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., No. 2018-1638
`
`(Fed. Cir.) (mandate issued November 20, 2018) (updated);
`
`St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., No. 18-___ (U.S.)
`
`(petition for certiorari filed December 20, 2018) (updated); and
`
`
`-1-
`
`
`
`U.S. Patent Application No. 15/585,320 (restriction requirement entered
`
`July 5, 2018).
`
`C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Unchanged
`
`
`
`D. Electronic Service – Unchanged
`
`
`
`Dated: January 7, 2019
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee
` Reg. No. 31,990
`
`
`
`
`
`-2-
`
`
`
`CERTIFICATE OF SERVICE
`This is to certify that I caused to be served a true and correct copy of the
`
`
`
`foregoing Petitioner Mylan Pharmaceuticals Inc.’s Mandatory Change-of-
`
`Information Notices on this 7th day of January, 2019, on the Patent Owner at the
`
`correspondence address of Allergan, Inc. and St. Regis Mohawk Tribe as follows:
`
`Dorothy P. Whelan
`Michael Kane
`Susan Morrison Colletti
`Robert M. Oakes
`Jonathan Singer
`Fish & Richardson P.C.
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Email: IPR13351-0008IP1@fr.com
`Email: IPR13351-0008IP2@fr.com
`Email: IPR13351-0008IP3@fr.com
`Email: IPR13351-0008IP4@fr.com
`Email: IPR13351-0008IP5@fr.com
`Email: IPR13351-0008IP6@fr.com
`Email: PTABInbound@fr.com
`
`Alfonso Chan
`Joseph DePumpo
`Michael W. Shore
`Christopher L. Evans
`Shore Chan DePumpo LLP
`901 Main Street, Suite 3300
`Dallas, TX 75201
`Email: achan@shorechan.com
`Email: jdepumpo@shorechan.com
`Email: mshore@shorechan.com
`Email: cevans@shorechan.com
`
`-3-
`
`
`
`And on the remaining petitioners as follows:
`
`
`Gary Speier
`Mark Schuman
`Ralph Wilson Powers III
`CARLSON, CASPERS, VANDENBURGH,
`LINDQUIST & SCHUMAN, P.A.
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Email: gspeier@carlsoncaspers.com
`Email: mschuman@carlsoncaspers.com
`Email: IPRCyclosporine@carlsoncaspers.com
`Email: tpowers-PTAB@sternekessler.com
`Email: PTAB@sternekessler.com
`
`Attorneys for Teva Pharmaceuticals USA, Inc.
`
`Michael Dzwonczyk
`Mark Boland
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`Email: mdzwonczyk@sughrue.com
`Email: mboland@sughrue.com
`Attorneys for Akorn Inc.
`
`
`
`Dated: January 7, 2019
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee, Lead Counsel
` Reg. No. 31,990
`
`
`
`
`
`-4-
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
